Molecular classification using Lund University algorithm and clinical correlations in muscle-invasive bladder cancer: Insights from a retrospective study
Background: Muscle-invasive bladder cancer (MIBC) is universally classified as high-grade urothelial carcinoma, precluding the use of histological grading alone for prognostication. However, specific morphological features of MIBC may provide useful information to guide treatment decisions. In the last decade, there has been increasing interest in genetic profiling of MIBC. Objective: The aim of the study is to validate the use of Lund Classification in attributing phenotype to large series with extreme reliability and reproducibility compared to all histological sections in the clinical practice. Methods: We performed a molecular profiling study on a large, consecutive cohort of MIBC cases using a straightforward immunohistochemical algorithm aligned with the Lund Classification. Results: We evaluated 450 MIBC cases. In a subgroup of 103 patients, we assessed the concordance between transurethral resection of bladder tumor (TURBT) specimens and cystectomy on paired samples. Luminal tumor types showed a statistically significant association with the usual histotype, while basal and NULL types were more frequently associated with variant histotypes (p < 0.0001). A stromal lymphocytic infiltrate ≥10% was more commonly observed in basal types (p < 0.0001). Basal types also exhibited higher positive rates of human epidermal growth factor receptor-2 (HER2/neu) positivity, while luminal types were more likely to be positive for tumor suppressor protein p53. Luminal types have demonstrated longer survival compared to their basal and NULL counterparts. In the concordance analysis, tumor type assignment based on TURBT showed sensitivity, specificity, and both positive and negative predictive values of 100% for basal and NULL types. The predictive accuracy for luminal types on TURBT ranged between 89.5% and 98.2%. Conclusion: Our findings demonstrate the feasibility of applying the Lund Classification for molecular subtyping of MIBC in routine diagnostics. The consistency in tumor type assignment between TURBT and cystectomy samples further supports the clinical utility of this approach. Tumor types significantly influenced survival outcomes, underscoring its relevance in patient stratification and personalized treatment strategies.
- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi: 10.3322/caac.21834
- Davarpanah NN, Yuno A, Trepel JB, Apolo AB. Immunotherapy: A new treatment paradigm in bladder cancer. Curr Opin Oncol. 2017;29(3):184-195. doi: 10.1097/CCO.0000000000000366
- Rosenberg JE. Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2007;7(12):1729-1736. doi: 10.1586/14737140.7.12.1729
- GLOBOCAN 2020: Bladder Cancer 10th Most Commonly Diagnosed Worldwide. SEER. Available from: https:// worldbladdercancer.org/news_events/globocan-2020 bladder-cancer [Last accessed on 2020 Nov 24].
- Meeks JJ, Al-Ahmadie H, Faltas BM, et al. Genomic heterogeneity in bladder cancer: Challenges and possible solutions to improve outcomes. Nat Rev Urol. 2020;17(5):259-270. doi: 10.1038/s41585-020-0304-1
- Witjes JA, Babjuk M, Bellmunt J, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort†: Under the auspices of the EAU-ESMO guidelines committees. Eur Urol. 2020;77(2):223-250. doi: 10.1016/j.eururo.2019.09.035
- Choi W, Ochoa A, McConkey DJ, et al. Genetic alterations in the molecular subtypes of bladder cancer: Illustration in the cancer genome atlas dataset. Eur Urol. 2017;72(3):354-365. doi: 10.1016/j.eururo.2017.03.010
- Sjödahl G, Lauss M, Lövgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377-3386. doi: 10.1158/1078-0432.CCR-12-0077-T
- Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;111(8):3110-3115. doi: 10.1073/pnas.1318376111
- Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007
- Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-322. doi: 10.1038/nature12965
- Rebouissou S, Bernard-Pierrot I, De Reyniès A, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med. 2014;6(244):244ra91. doi: 10.1126/scitranslmed.3008970
- Kamoun A, de Reyniès A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420-433. doi: 10.1016/j.eururo.2019.09.006
- Robertson AG, Meghani K, Cooley LF, et al. Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nat Commun. 2023;14(1):2126. doi: 10.1038/s41467-023-37568-9
- Necchi A, Giannatempo P, Paolini B, et al. Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy. Clin Genitourin Cancer. 2015;13(2):171-177.e1. doi: 10.1016/j.clgc.2014.08.002
- Warrick JI, Al-Ahmadie H, Berman DM, et al. International society of urological pathology consensus conference on current issues in bladder cancer. Working Group 4: Molecular subtypes of bladder cancer-principles of classification and emerging clinical utility. Am J Surg Pathol. 2024;48(1):e32-e42. doi: 10.1097/PAS.0000000000002053
- World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th revision, 5th ed. Geneva: World Health Organization; 2016.
- Sjödahl G, Jackson CL, Bartlett JM, Siemens DR, Berman DM. Molecular profiling in muscle-invasive bladder cancer: More than the sum of its parts. J Pathol. 2019;247(5):563-573. doi: 10.1002/path.5230
- American Cancer Society. Available from: https://www.cancer. org/cancer/types/bladder-cancer/detection-diagnosis-staging/ staging.html [Last accessed on 2024 Mar 12].
- Dadhania V, Zhang M, Zhang L, et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine. 2016;12:105-117. doi: 10.1016/j.ebiom.2016.08.036
- Minoli M, Kiener M, Thalmann GN, Kruithof-de Julio M, Seiler R. Evolution of urothelial bladder cancer in the context of molecular classifications. Int J Mol Sci. 2020;21(16):5670. doi: 10.3390/ijms21165670
- Jalanko T, de Jong JJ, Gibb EA, Seiler R, Black PC. Genomic subtyping in bladder cancer. Curr Urol Rep. 2020;21(2):9. doi: 10.1007/s11934-020-0960-y. Erratum in: Curr Urol Rep. 2020;21(7):25. doi: 10.1007/s11934-020-00977-0
- Sanguedolce F, Zanelli M, Palicelli A, et al. Are we ready to implement molecular subtyping of bladder cancer in clinical practice? Part 2: Subtypes and Divergent differentiation. Int J Mol Sci. 2022;23(14):7844. doi: 10.3390/ijms23147844
- Sanguedolce F, Zanelli M, Palicelli A, et al. Are we ready to implement molecular subtyping of bladder cancer in clinical practice? Part 1: General issues and marker expression. Int J Mol Sci. 2022;23(14):7819. doi: 10.3390/ijms23147819
- Wang CC, Tsai YC, Jeng YM. Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer. PLoS One. 2019;14(8):e0221785. doi: 10.1371/journal.pone.0221785
- Batista da Costa J, Gibb EA, Bivalacqua TJ, et al. Molecular characterization of neuroendocrine-like bladder cancer. Clin Cancer Res. 2019;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558
- Höglund M, Bernardo C, Sjödahl G, Eriksson P, Axelson H, Liedberg F. The Lund taxonomy for bladder cancer classification - from gene expression clustering to cancer cell molecular phenotypes, and back again. J Pathol. 2023;259(4):369-375. doi: 10.1002/path.6062
- Marzouka NA, Eriksson P, Bernardo C, et al. The lund molecular taxonomy applied to non-muscle-invasive urothelial carcinoma. J Mol Diagn. 2022;24(9):992-1008. doi: 10.1016/j.jmoldx.2022.05.006
- Marzouka, NA, Eriksson P, Rovira C, Liedberg F, Sjödahl G, Höglund M. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep. 2018;8(1):3737. doi: 10.1038/s41598-018-22126-x
- Zemanek T, Nova Z, Nicodemou A. Tumor-infiltrating lymphocytes and adoptive cell therapy: State of the art in colorectal, breast and lung cancer. Physiol Res. 2023;72(S3):S209-S224. doi: 10.33549/physiolres.935155
- Kawada T, Yanagisawa T, Rajwa P, et al. The prognostic value of tumor infiltrating lymphocytes after radical cystectomy for bladder cancer: A systematic review and meta-analysis. Clin Genitourin Cancer. 2024;22(2):535-543.e4. doi: 10.1016/j.clgc.2024.01.008
- Kardoust Parizi M, Margulis V, Compe Rat E, Shariat SF. The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis. Urol Oncol. 2021;39(1):15-33. doi: 10.1016/j.urolonc.2020.08.023
- Alifrangis C, McGovern U, Freeman A, Powles T, Linch M. Molecular and histopathology directed therapy for advanced bladder cancer. Nat Rev. 2019;16(8):465-483. doi: 10.1038/s41585-019-0208-0
- Reike MJ, de Jong JJ, Bismar TA, et al. Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers. Urol Oncol. 2024;42(6):177.e5-177.e14. doi: 10.1016/j.urolonc.2024.01.027
- Kollberg P, Chebil G, Eriksson P, Sjödahl G, Liedberg F. Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival. Urol Oncol. 2019;37(10):791-799. doi: 10.1016/j.urolonc.2019.04.010
- Damjanov I, Golubović M. Histopathology of urinary bladder carcinoma: Less common variants. Srp Arh Celok Lek. 2011;139(9-10):693-699.
- Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2- expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47-58. doi: 10.1200/JCO.23.02005